The role of MTHFR and MTRR gene polymorphisms in the development of cholelithiasis

In recent years, statistical studies show that cholelithiasis is detected in every fifth woman and every tenth man. Сholelithiasis is a multifactorial process that is influenced by both environmental and genetic factors. Some evidence suggests that total plasma homocysteine correlates with the presence of gallstones, suggesting that hyperhomocysteinemia is a risk factor for cholelithiasis. The aim of this work was to analyze the association of polymorphic variants of the methylenetetrahydrofolate reductase MTHFR (rs1801133 (677C>T), rs1801131 (1298A>C)) and methionine synthase reductase MTRR (rs1801394 (66A>G)) genes with the development of gallstone disease in individuals from the Republic of Bashkortostan. Material and methods. DNA samples from 196 patients with cholelithiasis and DNA samples from 274 individuals in the control group aged 23-87 years living in the Republic of Bashkortostan were used as research material. Genotyping was performed using the real-time PCR method. Results. It has been established that the rs1801133*T allele and the rs1801133*TT genotype of the MTHFR gene are markers of an increased risk of developing cholelithiasis. An association was established between the rs1801133*TT genotype of the rs1801133 polymorphic variant of the MTHFR gene and the moderate severity of cholelithiasis and hereditary burden in patients with cholelithiasis. A study of the polymorphic variant of the MTRR gene revealed that the rs1801394*G allele increases the risk of developing cholelithiasis. Analysis of associations of the polymorphic variant rs1801131 of the MTHFR gene with the development of cholelithiasis did not reveal statistically significant differences between the compared groups of patients and controls. Conclusion. Determination of homocysteine levels and genetic testing of polymorphic variants of MTHFR and MTRR in patients with cholelithiasis may be useful in clinical practice.

cholelithiasis, polymorphic variant, gene, methylenetetrahydrofolate reductase, methionine synthase reductase

1. Tazuma S. Homocysteine and gallstone diseases: is hyperhomocysteinemia a prerequisite for or secondary to gallstone formation?. J Gastroenterol. 2005. 40: 1085-1087. doi: 10.1007/s00535-005-1702-0.

2. Merzlikin N.V., Brazhnikova N.A., Al’perovich B.I., Chai V.F. Clinical Surgery. Manual in 2 volumes. Tomsk, TML-press. 2009; 2: 38-168. (in Russ.)@@ Мерзликин Н.В., Бражникова Н.А., Альперович Б.И., Цхай В.Ф. Клиническая хирургия. Руководство в 2 томах. Томск, ТМЛ-пресс. 2009; 2: 38-168.

3. Costa C.J., Nguyen M.T.T., Vaziri H., Wu G.Y. Genetics of Gallstone Disease and Their Clinical Significance: A Narrative Review. J Clin Transl Hepatol. 2024. 12(3): 316-326. doi: 10.14218/JCTH.2023.00563.

4. Nazki F.H., Sameer A.S., Ganaie B.A. Folate: metabolism, genes, polymorphisms and the associated diseases. Gene. 2014. 533 (1): 11-20. doi: 10.1016/j.gene.2013.09.063.

5. Li W.X., Cheng F., Zhang A.J. et al. Folate Deficiency and Gene Polymorphisms of MTHFR, MTR and MTRR Elevate the Hyperhomocysteinemia Risk. Clin. Lab. 2017. 63: 523-533. doi: 10.7754/Clin.Lab.2016.160917.

6. Wang Y., Du M., Vallis J. et al. The Roles of MTRR and MTHFR Gene Polymorphisms in Colorectal Cancer Survival. Nutrients. 2022. 14 (21): 45-94. doi: 10.3390/nu14214594.

7. Zhang J., Handy D.E., Wang Y. et al. Hyperhomocysteinemia from Trimethylation of Hepatic Phosphatidylethanolamine During Cholesterol Cholelithogenesis in Inbred Mice. Hepatology. 2011. 54 (2): 698-706.

8. Beksac K., Tanacan A., Cagan M. et al. Relationship of Cholelithiasis and Urolithiasis with Methylenetetrahydrofolate Reductase Polimorphisms. J Invest Surg. 2021. 34(10): 1104-1107.

9. Dixit R., Singh G., Pandey M. et al. Association of Methylenetetrahydrofolate Reductase Gene Polymorphism (MTHFR) in Patients with Callbladder Cancer. J Gastrointest Cancer. 2016. 47(1): 55-60.

10. Lu Y.T., Gunathilake M., Lee J. et al. Riboflavin intake, MTRR genetic polymorphism (rs1532268) and gastric cancer risk in a Korean population: a case-control study. Br J Nutr. 2021: 1-8. doi: 10.1017/S0007114521001811.

11. Wang P., Li S., Wang M., He J., Xi S. Association of MTRR A66G polymorphism with cancer susceptibility: Evidence from 85 studies. J Cancer. 2017. 8(2): 266-277. doi:10.7150/jca.17379.

12. Zhou D., Mei Q., Luo H. et al. The Polymorphisms in Methylenetetrahydrofolate Reductase, Methionine Synthase, Methionine Synthase Reductase, and the Risk of Colorectal Cancer.Int J Biol Sci. 2012. 8(6): 819-830. doi: 10.7150/ijbs.4462.

13. Sowton A.P., Padmanabhan N., Tunster S.J. et al. Mtrr hypomorphic mutation alters liver morphology, metabolism and fuel storage in mice. Mol Genet Metab Rep. 2020. 23:100580. doi: 10.1016/j.ymgmr.2020.100580.

14. Skvortsov V.V., Khalilova U.A. Diagnostics and treatment of cholelithiasis. Experimental and Clinical Gastroenterology. 2018. 157(9): 142-150. (in Russ.) doi: 10.31146/1682-8658-ecg-157-9-142-150.@@ Скворцов В.В., Халилова У.А. Диагностика и лечение желчнокаменной болезни. Экспериментальная и клиническая гастроэнтерология. 2018. 157(9): 142-150. doi: 10.31146/1682-8658-ecg-157-9-142-150.